Grantham, Mayo, Van Otterloo & Co (GMO)
RMD icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s ResMed RMD Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,923
Closed -$4.25M – 712
2026
Q1 		$4.25M Buy
+18,923
New +$4.72M 0.01% 345
2016
Q1 		– Sell
-37,303
Closed -$2M – 620
2015
Q4 		$2M Sell
37,303
-35,200
-49% -$1.98M 0.01% 336
2015
Q3 		$3.69M Sell
72,503
-37,400
-34% -$2.01M 0.01% 271
2015
Q2 		$6.2M Sell
109,903
-800
-0.7% -$50.5K 0.02% 232
2015
Q1 		$7.95M Sell
110,703
-200
-0.2% -$13K 0.02% 214
2014
Q4 		$6.22M Sell
110,903
-23,811
-18% -$1.24M 0.02% 237
2014
Q3 		$6.64M Sell
134,714
-40,600
-23% -$2.07M 0.02% 243
2014
Q2 		$8.88M Buy
175,314
+4,500
+3% +$223K 0.02% 210
2014
Q1 		$7.63M Buy
170,814
+84,343
+98% +$3.79M 0.02% 232
2013
Q4 		$4.07M Sell
86,471
-329
-0.4% -$16.7K 0.01% 341
2013
Q3 		$4.58M Buy
86,800
+24,458
+39% +$1.19M 0.01% 322
2013
Q2 		$2.81M Buy
+62,342
New +$2.96M 0.01% 367

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s RMD Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of ResMed (RMD) in Q2 2026, closing a stake of 18,923 shares — an estimated $4.25M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in RMD in Q2 2013 and held it in 12 quarters. The position peaked at $8.88M in Q2 2014. 887 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining ResMed position as of Q2 2026 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 18,923 ResMed shares in Q2 2026, an estimated $4.25M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ResMed in Q2 2013 and held it in 12 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s ResMed position peaked at $8.88M in Q2 2014.
  • 887 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.